Guardian Pharmacy Services, Inc. (NYSE:GRDN) Stock Has Consensus Price Target of $43.83 According to Brokerages

Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) have received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $45.57.

Several equities research analysts recently commented on the stock. Oppenheimer lifted their price target on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research note on Friday, August 7th. Wall Street Zen lowered Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a report on Saturday, September 19th. Truist Financial lifted their target price on Guardian Pharmacy Services from $47.00 to $51.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Weiss Ratings raised Guardian Pharmacy Services from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, August 20th. Finally, KeyCorp began coverage on Guardian Pharmacy Services in a research report on Tuesday, September 22nd. They issued an “overweight” rating and a $52.00 target price for the company.

Hedge Funds Weigh In On Guardian Pharmacy Services

A number of hedge funds have recently modified their holdings of GRDN. Clearstead Advisors LLC increased its position in Guardian Pharmacy Services by 196.3% in the 4th quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock valued at $79,000 after acquiring an additional 1,741 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Guardian Pharmacy Services by 3.2% in the 1st quarter. Bank of New York Mellon Corp now owns 69,432 shares of the company’s stock valued at $2,615,000 after purchasing an additional 2,177 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Guardian Pharmacy Services by 53.0% in the second quarter. Arizona State Retirement System now owns 8,393 shares of the company’s stock valued at $351,000 after purchasing an additional 2,907 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Guardian Pharmacy Services by 67.4% in the first quarter. The Manufacturers Life Insurance Company now owns 11,820 shares of the company’s stock valued at $445,000 after purchasing an additional 4,761 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of Guardian Pharmacy Services during the first quarter worth approximately $253,000.

Key Stories Impacting Guardian Pharmacy Services

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: KeyCorp’s new coverage establishes a bullish outlook for Guardian Pharmacy Services, with analyst Z. Haggerty projecting EPS of $1.16 for fiscal 2026, $1.27 for fiscal 2027 and $1.46 for fiscal 2028. The estimates suggest continued earnings growth and provide a fundamental basis for the $52 target. Guardian Pharmacy Services Stock Rated Overweight in New Coverage at KeyCorp
• Positive Sentiment: KeyCorp’s quarterly projections call for EPS of $0.27 in Q3 2026, $0.36 in Q4 2026 and $0.28, $0.28, $0.30 and $0.40 in the four quarters of 2027. The rising quarterly outlook, particularly toward late 2027, reinforces expectations for operating and earnings momentum.
• Neutral Sentiment: KeyCorp’s fiscal 2026 EPS estimate of $1.16 is slightly below the broader consensus estimate of $1.19, which could temper enthusiasm in the near term. However, its longer-term estimates point to acceleration in 2027 and 2028. KeyBanc initiates coverage of Guardian Pharmacy Services at overweight

Guardian Pharmacy Services Stock Up 0.1%

Shares of GRDN opened at $41.25 on Monday. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of 40.05, a price-to-earnings-growth ratio of 2.15 and a beta of 0.06. Guardian Pharmacy Services has a 52-week low of $23.14 and a 52-week high of $48.33. The stock has a 50 day moving average price of $40.77 and a 200 day moving average price of $39.26.

Guardian Pharmacy Services (NYSE:GRDN) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The company had revenue of $351.77 million for the quarter, compared to analysts’ expectations of $340.45 million. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. On average, equities analysts anticipate that Guardian Pharmacy Services will post 1.18 EPS for the current fiscal year.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc is a long-term care pharmacy company that provides prescription medications and related pharmacy services to residents of assisted living communities, skilled nursing facilities, memory care centers and other institutional care settings.

The company’s services include medication dispensing and packaging, prescription delivery, medication management, pharmacy consulting and clinical support. Guardian works with care providers, residents and their families to help coordinate medication regimens, improve adherence and support the ongoing pharmacy needs of patients who may require complex or recurring treatments.

Guardian Pharmacy Services operates through a network of community-based pharmacies serving long-term care customers in multiple U.S.